13 results
8-K
EX-1.1
7at c2deh
12 May 22
Entry into a Material Definitive Agreement
8:31am
8-K
EX-10.1
eoi7qfepo4ul4od6
24 Nov 21
Seelos Therapeutics Announces Acquisition of an Exclusive License of iX Biopharma’s Proprietary Wafer-Based Delivery Platform for Sublingual Ketamine
8:20am
8-K
EX-1.1
5sgq5lrz avdu18
21 May 21
Seelos Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock
12:00am
8-K
EX-10.2
4eyjw7o
16 Oct 18
Entry into a Material Definitive Agreement
8:57pm
425
EX-10.2
d0vq1ma94l6 byzxn0
16 Oct 18
Business combination disclosure
8:56pm
- Prev
- 1
- Next